X4 Pharmaceuticals Reports Third-Quarter 2026 Results and Corporate Update
The update says the 4WARD Phase 3 chronic neutropenia trial is expected to achieve target enrollment in Q4 2026.
Related stories
Great Elm Group Q1 Revenue Drops on Property Sale Timing
Great Elm Group reported lower Q1 revenue, citing the timing of property sales.
M impact | EQUITY | Nov 04, 2026, 10:09 PM UTC
Vaxcyte Q3 Loss Smaller Than Estimates; Plans VAX-31 Filing in H1 2028
Vaxcyte reported a Q3 loss smaller than estimates and plans to file VAX-31 in the first half of 2028.
M impact | EQUITY | Nov 04, 2026, 10:09 PM UTC
Mercado Libre Q3 Revenue and Financial Income Rise 45% to $10.75 Billion
Mercado Libre reported third-quarter net revenue and financial income of $10.75 billion, up 45% year over year. Brazil delivered the strongest growth.
M impact | EQUITY | Nov 04, 2026, 10:09 PM UTC
Genworth Financial Posts Q3 Net Loss on Closed Block Weakness
Genworth Financial reported a third-quarter net loss, citing weakness in its Closed Block segment.
M impact | EQUITY | Nov 04, 2026, 10:08 PM UTC
B2Gold Reports Q3 Results, Lowers Annual AISC Guidance
B2Gold lowered its annual all-in sustaining cost guidance and said it remains on track to achieve production guidance.
M impact | EQUITY | Nov 04, 2026, 10:08 PM UTC
Eversource Q3 GAAP Earnings Fall 6% to $346 Million
M impact | EQUITY | Nov 04, 2026, 10:08 PM UTC